Matinas BioPharma
MTNB
45 hedge funds and large institutions have $8.74M invested in Matinas BioPharma in 2018 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 8 reducing their positions, and 9 closing their positions.
88% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 8
0% more ownership
Funds ownership: 0.24% → 0.24% (+0%)
8% less funds holding
Funds holding: 49 → 45 (-4)
33% less capital invested
Capital invested by funds: $13M → $8.74M (-$4.22M)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$476K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$89.5K |
| 3 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
+$31.7K |
| 4 |
State Street
Boston,
Massachusetts
|
+$21.9K |
| 5 |
Morgan Stanley
New York
|
+$20.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
American Century Companies
Kansas City,
Missouri
|
-$155K |
| 2 |
VF
Virtu Financial
New York
|
-$123K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$61.9K |
| 4 |
SG Americas Securities
New York
|
-$50K |
| 5 |
Goldman Sachs
New York
|
-$41.4K |
MTNB Hedge Fund Activity: Q1 2018 in Review
45 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q1 2018, worth a combined $8.74M — down 33% from $13M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of MTNB and 6 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 15 added.
The largest buyer was Royal Bank of Canada, adding an estimated $476K. The largest seller was American Century Companies, exiting entirely with an estimated $155K sold.
- 45 institutional investors held Matinas BioPharma (MTNB) as of Q1 2018, down from 49 in Q4 2017.
- Funds reported $8.74M of Matinas BioPharma stock for Q1 2018, down 33% quarter-over-quarter.
- 6 funds opened new Matinas BioPharma positions in Q1 2018 and 9 closed out, a net change of -3 holders.
- The largest Matinas BioPharma buyer in Q1 2018 was Royal Bank of Canada, an estimated $476K added.
- The largest Matinas BioPharma seller in Q1 2018 was American Century Companies, an estimated $155K sold.
Based on aggregated 13F filings for Q1 2018.